The data come from a systematic review of over 90 studies between 1952 through 2022, which found that both prevalence and ...

Gravis Capital chief executive Phil Kent has cautioned chancellor Rachel Reeves against forcing pension funds to commit cash ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

The researchers validated their AI-powered solution using 102 telemedicine videos from 51 patients who have myasthenia gravis ...

Myasthenia gravis is a chronic condition that causes muscles to tire and weaken easily. For example, if you have myasthenia gravis, you may notice that during a meal, your jaw muscles become tired ...

Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Statin drugs modestly reduce the risk of vascular disease complications, including stroke, heart attack and death, when given ...

Investigational nipocalimab reduced serum immunoglobulin G (IgG), improved functional scores, and was well tolerated in ...

SAVANNAH, Ga. — Should patients with myasthenia gravis (MG) continue to undergo the traditional therapy of immunosuppression with drugs like corticosteroids and nonsteroidal agents? Or is it time to ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window So number one, MINT represents one of the largest-to-date ...

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

Unlimited access to all stories from nashuatelegraph.com on your computer, tablet or smart phone. Access nashuatelegraph.com, view our digital edition or use our Full ...